

F. No. 8(64)/2019/DP/NPPA/Div.II
भारत सरकार
Government of India
रसायन और उर्वरक मंत्रालय
Ministry of Chemicals & Fertilizers
औषध विभाग
Department of Pharmaceuticals
राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण
National Pharmaceutical Pricing Authority

तीसरी/पांचवी मंजिल 5th / 3rd Floor,
वाई.एम.सी.ए. सांस्कृतिक केन्द्र बिल्डिंग
YMCA Cultural Center Building,
1, जय सिंह रोड, नई दिल्ली-110001
1, Jai Singh Road, N. Delhi – 110001.
दिनांक :- 08.03.2019

OFFICE MEMORANDUM

Subject : Trade Margin Rationalisation of select Non-scheduled Anti-Cancer Drugs under paragraph 19 of DPCO, 2013.


National Pharmaceutical Pricing Authority (NPPA) vide Order SO No. 1041(E) dated 27.02.2019 put a cap of 30% Trade margin on Selling Price for the non-scheduled Anti-Cancer formulations containing any of the 42 drugs listed therein by invoking paragraph 19 of DPCO, 2013.

2. The NPPA directed manufacturers to fix their retail price based on price at first point of sale of product (referred as Price to Stockist), as per formula in Table A of aforesaid Order, of the non-scheduled formulations containing any of the 42 Non-Scheduled anti cancer drugs listed in the aforesaid Order (whether individual or in combination, irrespective of dosage strength, dosage form and /or route of administration).

3. The NPPA also directed manufacturers to provide the revised MRP of their formulations in Annexure I (details of PTS and MRP arrived for formulations by using the formula prescribed) of Order dated 27.02.2019 in respect of all non-scheduled formulations containing drugs as per Table B, irrespective whether there was any change in MRP or not, by 6th March, 2019, under paragraph 9(2) of the DPCO, 2013.

4. Further, information was also sought from 10 hospitals regarding these 42 drugs, to capture institutional data.

5. The revised MRP in respect of formulations arrived from these 42 drugs as per data provided by manufacturers, is at Annexure-X.
6. The revised prices shall come into effect from 8th March, 2019.
7. The onus of providing correct information rests with the manufacturer. The manufacturer will be liable for any aberration arising out of incorrect information or withholding correct information from NPPA.
8. It is further reiterated that the trade margin cap notified by S.O. No. 1041(E) dated 27.02.2019 is applicable on All the brands containing any of the 42 drugs listed in aforesaid Order, irrespective of whether the brand/ formulation is included in the Annexure attached herewith.
9. All other conditions for non-scheduled formulations as per the provisions of DPCO, 2013 shall be applicable to the 42 drugs under reference.
10. The manufacturers not complying with the price arrived at through S.O. No. 1041(E) dated 27.02.2019 and notes therein, are liable to be acted against, under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.



(Amarpal Singh Sawhney)
Director (Pricing)